Buprenorphine Pharmacotherapy and Behavioral Treatment: Comparison of Outcomes Among Prescription Opioid Users, Heroin Users and Combination Users

Overview

Journal J Subst Abuse Treat

Specialty Psychiatry

Date 2014 Jul 29

PMID 25065489

Citations 15

Authors

Suzanne Nielsen

Maureen Hillhouse

Larissa Mooney

Alfonso Ang

Walter Ling

Affiliations

Soon will be listed here.

Abstract

Most research examining buprenorphine has been conducted with heroin users. Few studies have examined buprenorphine pharmacotherapy for prescription opioid users. Data were from a randomized controlled trial of behavioral treatment provided for 16weeks on a platform of buprenorphine pharmacotherapy and medication management. We compared heroin (H, n=54), prescription opioid (PO, n=54) and combination heroin+prescription opioid (POH, n=71) users to test the hypothesis that PO users will have better treatment outcomes compared with heroin users. The PO group provided more opioid-negative urine drug screens over the combined treatment period (PO:70%, POH:40%, H:38%, p<0.001) and at the end of the combined treatment period (PO:65%, POH:31%, H:33%, p<0.001). Retention was lowest in the H group (PO:80%, POH:65%, H:57%, p=0.039). There was no significant difference in buprenorphine dose between the groups. PO users appear to have better outcomes in buprenorphine pharmacotherapy compared to those reporting any heroin use, confirming that buprenorphine pharmacotherapy is effective in PO users.

Citing Articles

Pharmacological Strategies to Decrease Long-Term Prescription Opioid Use: A Systematic Review.

Ellerbroek H, Kalkman G, Kramers C, Schellekens A, van den Bemt B J Clin Med. 2025; 13(24.

PMID: 39768692 PMC: 11728354. DOI: 10.3390/jcm13247770.

Protocol for harmonization of randomized trials testing the addition of behavioral therapy to buprenorphine for opioid use disorder.

McHugh R, Bailey A, Weiss R, Fitzmaurice G Drug Alcohol Depend Rep. 2024; 11:100226.

PMID: 38545409 PMC: 10966146. DOI: 10.1016/j.dadr.2024.100226.

Opioid agonist treatment for people who are dependent on pharmaceutical opioids.

Nielsen S, Tse W, Larance B Cochrane Database Syst Rev. 2022; 9:CD011117.

PMID: 36063082 PMC: 9443668. DOI: 10.1002/14651858.CD011117.pub3.

Treatment-seeking behaviour among people with opioid use disorder in the high-income countries: A systematic review and meta-analysis.

Hall N, Le L, Majmudar I, Teesson M, Mihalopoulos C PLoS One. 2021; 16(10):e0258620.

PMID: 34653220 PMC: 8519451. DOI: 10.1371/journal.pone.0258620.

Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings.

Krawczyk N, Williams A, Saloner B, Cerda M J Subst Abuse Treat. 2021; 126:108329.

PMID: 34116820 PMC: 8197774. DOI: 10.1016/j.jsat.2021.108329.

References

Childress A, McLellan A, OBrien C . Abstinent opiate abusers exhibit conditioned craving, conditioned withdrawal and reductions in both through extinction. Br J Addict. 1986; 81(5):655-60. DOI: 10.1111/j.1360-0443.1986.tb00385.x. View

Paulozzi L . Prescription drug overdoses: a review. J Safety Res. 2012; 43(4):283-9. DOI: 10.1016/j.jsr.2012.08.009. View

Compton W, Volkow N . Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2005; 81(2):103-7. DOI: 10.1016/j.drugalcdep.2005.05.009. View

Nielsen S, Hillhouse M, Thomas C, Hasson A, Ling W . A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. J Addict Med. 2012; 7(1):33-8. PMC: 3567310. DOI: 10.1097/ADM.0b013e318277e92e. View

Brewer D, Catalano R, Haggerty K, Gainey R, Fleming C . A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction. 1998; 93(1):73-92. View

Fischer B, Nakamura N, Rush B, Rehm J, Urbanoski K . Changes in and characteristics of admissions to treatment related to problematic prescription opioid use in Ontario, 2004-2009. Drug Alcohol Depend. 2010; 109(1-3):257-60. DOI: 10.1016/j.drugalcdep.2010.02.001. View

Ling W, Shoptaw S, Wesson D, Rawson R, Compton M, KLETT C . Treatment effectiveness score as an outcome measure in clinical trials. NIDA Res Monogr. 1997; 175:208-20. View

Moore B, Fiellin D, Barry D, Sullivan L, Chawarski M, OConnor P . Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med. 2007; 22(4):527-30. PMC: 1829433. DOI: 10.1007/s11606-007-0129-0. View

Ware Jr J, Sherbourne C . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30(6):473-83. View

10.

Maxwell J . The prescription drug epidemic in the United States: a perfect storm. Drug Alcohol Rev. 2011; 30(3):264-70. DOI: 10.1111/j.1465-3362.2011.00291.x. View

11.

Nielsen S, Hillhouse M, Mooney L, Fahey J, Ling W . Comparing buprenorphine induction experience with heroin and prescription opioid users. J Subst Abuse Treat. 2012; 43(3):285-90. PMC: 3350757. DOI: 10.1016/j.jsat.2011.12.009. View

12.

McLellan A, Kushner H, Metzger D, Peters R, Smith I, Grissom G . The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992; 9(3):199-213. DOI: 10.1016/0740-5472(92)90062-s. View

13.

Nielsen S, Dietze P, Lee N, Dunlop A, Taylor D . Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction. 2007; 102(4):616-22. DOI: 10.1111/j.1360-0443.2006.01731.x. View

14.

Ling W, Wesson D . Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend. 2003; 70(2 Suppl):S49-57. DOI: 10.1016/s0376-8716(03)00059-0. View

15.

Lintzeris N, Nielsen S . Benzodiazepines, methadone and buprenorphine: interactions and clinical management. Am J Addict. 2010; 19(1):59-72. DOI: 10.1111/j.1521-0391.2009.00007.x. View

16.

Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J . Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction. 2013; 108(10):1788-98. PMC: 3866908. DOI: 10.1111/add.12266. View

17.

Warner M, Chen L, Makuc D . Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. NCHS Data Brief. 2009; (22):1-8. View

18.

Caplehorn J, Drummer O . Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. Aust N Z J Public Health. 2002; 26(4):358-62; discussion 362-3. DOI: 10.1111/j.1467-842x.2002.tb00185.x. View

19.

Brands B, Blake J, Sproule B, Gourlay D, Busto U . Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug Alcohol Depend. 2004; 73(2):199-207. DOI: 10.1016/j.drugalcdep.2003.10.012. View

20.

Wesson D, Ling W . The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003; 35(2):253-9. DOI: 10.1080/02791072.2003.10400007. View